About Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Loxo Oncology, Inc.
2
Clinical Trials at Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
During the past decade, Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
2021-03-09
2027-05-01
Recruiting
250
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
2021-09-23
2026-07-01
Recruiting
250
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)"
#1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
According to Clinical.Site data, the most researched conditions in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)" are
"Chronic Lymphocytic Leukemia" (2 trials) and "Small Lymphocytic Lymphoma" (2 trials). Many other conditions were trialed in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)" in a lesser frequency.
Clinical Trials Intervention Types at Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
Most popular intervention types in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Bendamustine" (2 trials), "Rituximab" (2 trials), "Idelalisib" (1 trials), "LOXO-305" (1 trials) and "Pirtobrutinib" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
The vast majority of trials in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)" are
2 trials for "All" genders.
Clinical Trials Status at Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
Currently, there are NaN active trials in "Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)".
undefined are not yet recruiting,
2 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich),
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich), 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".